The fertility company Spermosens recently announced that they have entered into a memorandum of understanding, a so-called MoU, with the USA-based medical technology company RSI Technology Group. The agreement focuses on evaluating the conditions for introducing the company's diagnostic method Juno-Checked to the American fertility market.RSI develops equipment for the collection and preparation of semen samples. Within the framework of the MoU, the parties will evaluate how Juno-Checked can be used on samples handled with RSI's products to add clinically relevant information about male fertility.- USA is a strategically very important market for us. The purpose of the collaboration with RSI is to evaluate the prerequisites for a future commercial launch, says Spermosens CEO Tore Lund Hansen to Finwire, and adds:- If the evaluation turns out well, RSI's infrastructure gives us a potential path into the American market, but exactly what that model will look like is part of the ongoing discussions.This is seen as a first, non-binding step. The evaluation begins immediately without a fixed timeline, and a final agreement presupposes consensus on technology, market, and commercial terms.The MoU with RSI differs from the letter of intent that Spermosens signed on January 16 with Sapyen, which focuses on a global evaluation of a home-based testing service.- We are simultaneously evaluating different collaborations and markets to support a future introduction of Juno-Checked to fertility clinics and patients.Do you have more discussions underway?- We are in an expansive phase and are in ongoing dialogue with potential partners. We communicate when there is something concrete to report, but this type of process always involves evaluations and negotiations, concludes Tore Lund Hansen.